Identification and validation of the methylation biomarkers of non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Shicheng Guo
Fengyang Yan
Jibin Xu
Yang Bao
Ji Zhu
Xiaotian Wang
Junjie Wu
Yi Li
Weilin Pu
Yan Liu
Zhengwen Jiang
Yanyun Ma
Xiaofeng Chen
Momiao Xiong
Li Jin
Jiucun Wang
机构：
[1] Collaborative Innovation Center for Genetics and Development,State Key Laboratory of Genetic Engineering and Ministry of Education Key Laboratory of Contemporary Anthropology
[2] School of Life Sciences and Institutes of Biomedical Sciences,Department of Cardiothoracic Surgery
[3] Fudan University Jiangwan Campus,Department of Cardiothoracic Surgery
[4] Changzheng Hospital of Shanghai,Department of Pneumology
[5] Yangzhou No.1 People’s Hospital,Center for Genetic & Genomic Analysis
[6] Changhai Hospital of Shanghai,Department of Cardiothoracic Surgery
[7] Changhai Hospital of Shanghai,Human Genetics Center
[8] Genesky Biotechnologies Inc.,undefined
[9] Huashan Hospital,undefined
[10] Fudan University,undefined
[11] The University of Texas School of Public Health,undefined
[12] Fudan-Taizhou Institute of Health Sciences,undefined
来源：
Clinical Epigenetics | 2015年 / 7卷
关键词：
Non-small cell lung cancer; DNA methylation; Biomarker; Batch effect elimination; Diagnosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Proteomics biomarkers for non-small cell lung cancer
    Kisluk, Joanna
    Ciborowski, Michal
    Niemira, Magdalena
    Kretowski, Adam
    Niklinski, Jacek
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2014, 101 : 40 - 49
  • [42] Biomarkers in non-small cell lung cancer prevention
    Hilbe, W
    Dirnhofer, S
    Greil, R
    Wöll, E
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2004, 13 (05) : 425 - 436
  • [43] Biomarkers of immunotherapy in non-small cell lung cancer
    Wang, Lingling
    Hu, Yue
    Wang, Shengchao
    Shen, Jiali
    Wang, Xiaochen
    ONCOLOGY LETTERS, 2020, 20 (05)
  • [44] Emerging biomarkers in non-small cell lung cancer
    Greillier, L.
    ONCOLOGIE, 2012, 14 (05) : 316 - 319
  • [45] Plasma metabolite biomarkers for EGFR-mutated non-small cell lung cancer (NSCLC)
    Thamlikitkul, Lucksamon
    Manocheewa, Siriphan
    Limjiasahapong, Suphitcha
    Wanichthanarak, Kwanjeera
    Panya, Atikorn
    Poungvarin, Naravat
    Pomyen, Yotsawat
    Khoomrung, Sakda
    CANCER RESEARCH, 2024, 84 (06)
  • [46] Serum autoantibodies as prognostic biomarkers for stage IV non-small cell lung cancer (NSCLC).
    Pergande, Melissa R.
    Piper, Clinton T.
    Fhied, Cristina L.
    Mahon, Brett
    Fidler, Mary J.
    Bonomi, Philip
    Borgia, Jeffrey Allen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Identification and validation of MTAP as a potential biomarker for non-small cell lung cancer
    Zhang, K. T.
    Li, B. Y.
    Qian, X. H.
    Ying, W. T.
    MOLECULAR & CELLULAR PROTEOMICS, 2004, 3 (10) : S59 - S59
  • [48] Whole Exome Sequencing (WES) in Non-Small Cell Lung Carcinoma (NSCLC): Identification of Novel Biomarkers
    Singh, V.
    Katiyar, A.
    Malik, P.
    Mohan, A.
    Singh, H.
    Jain, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S574 - S574
  • [49] Non-small cell lung cancer (NSCLC) in elderly patients
    Batura-Gabryel, H.
    Brajer, B.
    LUNG CANCER, 2006, 52 : S19 - S19
  • [50] CHEMOTHERAPY IN NON-SMALL CELL LUNG-CANCER (NSCLC)
    KLASTERSKY, J
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (07): : 1035 - 1038
12345